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Anemia of cancer and chronic inﬂammatory diseases is a frequent complication aﬀecting quality of life. For cancer patients
it represents a particularly bad prognostic. Low level of erythropoietin is considered as one of the causes of anemia in these
pathologies. The deﬁciency in erythropoietin production results from pro-inﬂammatory cytokines eﬀect. However, few data is
available concerning molecular mechanisms involved in cytokine-mediated anemia. Some recent publications have demonstrated
the direct eﬀect of pro-inﬂammatory cytokines on cell diﬀerentiation towards erythroid pathway, without erythropoietin defect.
This suggested that pro-inﬂammatory cytokine-mediated signaling pathways aﬀect erythropoietin activity. They could interfere
with erythropoietin-mediated signaling pathways, inducing early apoptosis and perturbing the expression and regulation of
speciﬁc transcription factors involved in the control of erythroid diﬀerentiation. In this review we summarize the eﬀect of
tumor necrosis factor (TNF)α, TNF-related apoptosis-inducing ligand (TRAIL), and interferon (IFN)-γ on erythropoiesis with
a particular interest for molecular feature.
Copyright © 2009 F. Morceau et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Anemiarepresentsafrequentcomplicationincancerpatients
aswellasinchronicinﬂammatorydiseases.Itisanimportant
causeofcancer-relatedfatigue[1],whichconsiderablyaﬀects
quality of life. Anemia is in fact considered as a bad
prognostic factor for survival regardless of tumor type [2].
Up to 40% of cancer patients are anemic at diagnosis [3, 4]
and the frequency even increases following chemotherapy
[5]. This incidence varies according to the stage and the
t u m o rt y p ea sw e l la sp a t i e n ta g e .M o r e o v e r ,t u m o rr e s p o n -
siveness to radiotherapy seems to be weakened in the case
of anemia [6]. In substitution to blood transfusion as anti-
anemiatherapy,someerythroidstimulatingagentshavebeen
developed including human recombinant erythropoietin
(hrEpo). Despite this treatment improves quality of life by
alleviating anemia, the use of hrEpo as a treatment for
cancer related anemia could be inappropriate for cancer
patients. Indeed, based on clinical trials [7, 8]h r E p ow a s
suspected to trigger tumor progression leading to decreased
survival.
The essential role of circulating erythrocytes is the
transport of oxygen to the tissues. Oxygen is bound to
hemoglobin within erythrocytes that makes them highly
prone to oxidative damage [9]. For this reason, erythroid
cells contain numerous antioxidant enzymes to protect them
against oxygen radicals [10] and deﬁcient protection from
reactive oxygen species (ROS) results in disease of red blood
cells including anemia [11]. In fact, there are several causes
of cancer-associated anemia including mechanical inﬂuence
of the tumor on blood ﬂow, and mainly the immune
system activation with autoantibody formation and pro-
inﬂammatory cytokines production [12]. Indeed, in vivo
and in vitro studies have demonstrated the implication of
interferon (IFN)-γ, tumour-necrosis factor (TNF)-α,T N F -
related apoptosis-inducing ligand (TRAIL) and interleukin
(IL)-1 [13–18] in the inhibition of the proliferation, and
diﬀerentiation of erythroid progenitor cells. Moreover, ane-
mia in children with solid tumours was related to IFNγ and
TNFα [19]. In fact, pro-inﬂammatory cytokines were shown
to trigger the suppression of renal erythropoietin production
and therefore erythropoiesis. Inhibition of Epo production2 Mediators of Inﬂammation
was shown in vitro and in vivo to potentially involve IFNγ,
IL-1 and -6, and TNFα [20–22].
However, according to Spivak [12], the suppression of
erythropoietin production in inﬂammatory conditions such
as cancers, cannot be the solely explanation for anemia
since the level of plasma erythropoietin is not aﬀected
in a suﬃcient amount. In this respect, hematopoietic
stem/progenitor cells (HSPC) express receptors for pro-
inﬂammatory cytokines [12] and several studies demon-
strated that a direct action of the cytokines on hematopoietic
cell lines in vitro could impair erythroid development
and the number of erythroid progenitor cells [23–26].
Moreover, cytokines act in a microenvironment where they
are produced and supposed to be concentrated, rather than
in circulating blood. Indeed, poor correlation has been
reported between circulating cytokine levels and the high
cellular cytokine production [27]. Furthermore, marrow-
adherent cells from patients with the anemia of chronic
disease suppressed erythroid progenitors [28]. The molec-
ular mechanisms involved in pro-inﬂammatory cytokine-
mediated anemia, apart from Epo down-regulation and iron
metabolism deﬁciency, are poorly described. For that reason,
we aim to review the current knowledge concerning the
direct eﬀect of pro-inﬂammatory cytokines on erythroid cell
diﬀerentiation, especially on signal transduction pathways
and the regulation of erythrospeciﬁc genes expression in the
pro-inﬂammatory-mediated inhibition of erythroid diﬀer-
entiation. We will then focus on molecular regulation of ery-
throid diﬀerentiation rather than on iron or erythropoietin
involvement in anemia.
2.MolecularRegulation of
ErythroidDifferentiation
Expansion and diﬀerentiation of erythroid progenitor cells
are dependent on growth factors and hormones network,
acting in a thinly regulated chronology. Epo is the main
erythropoietic hormone, acting by interaction with its spe-
ciﬁc membrane receptor EpoR. Stimulation of EpoR triggers
the activation of signaling pathways required for survival,
proliferation, and diﬀerentiation of erythroblasts. Another
important cytokine involved in erythropoiesis is the stem
cell factor (SCF), a ligand of the membrane receptor c-Kit.
Signal transduction pathways activated by SCF have been
reported to delay diﬀerentiation and to enhance progenitors
proliferation in cooperation with Epo [29, 30].
EpoR is a homodimer constitutively associated with
Janus tyrosine kinase 2 (Jak2). The activation of Jak2 results
from the ligand binding-induced conformational change of
the EpoR dimer [31, 32]. Activated Jak2 induces phospho-
rylation of the tyrosine kinase RON that activates PI3K
via the docking molecule Grb2-associated binder (Gab)1
[33] also reported as phosphorylated after stimulation of
EpoR [34]. Activation of the PI3K substrate AKT/PKB
induces downregulation of the cell cycle inhibitor p27/kip1
expression [35] via inhibition of the transcription factor
forkhead box 03a (FOXO3a) [36] ,ad o w n s t r e a mt a r g e to f
EpoR/PI3K/AKTsignalingpathway.Moreover,thetranscrip-
tion factor FOXO3a has been recently reported as one of
the main regulators of oxidative stress in erythropoiesis [37].
In fact, FOXO3a is inactivated by Epo signaling pathway
and its expression as well as its transcriptional activity is
enhanced during the maturation of erythroid precursor cells
when EpoR expression decreases. In the presence of Epo
and in the case of the loss of FOXO3a, ROS mediate the
decrease in lifespan of circulating erythrocytes as well as
the rate of erythroid cell maturation. This suggested that
FOXO3 is required for the regulation of oxidative stress in
erythropoiesis.
The cell-signaling cascade initiated by Epo-dependent
Jak2 activation, leads to erythroblast expansion. Moreover,
PI3K activation mediates the mitogen-activated protein
kinase (MAPK, ERK1/2) path in correlation with the
expansion of erythroblasts [38]. Another EpoR-mediated
pathway leading to cell proliferation involves the Ras-Raf-
MEK-ERK pathway [39–43] upon recruitment of the Grb2-
Sos adapter molecules to the EpoR [44,45]. Phosphorylation
of the kinase Raf1 [39] has been shown to delay erythroblast
diﬀerentiation by restraining the caspase-3 activation [46].
Moreover, EPO and SCF activate Jun-N terminal kinase
(JNK) promoting proliferation and survival of hematopoi-
etic cells [47, 48].
On the other hand, Epo-induced diﬀerentiation of ery-
throid cells is also dependent on PI3K/Akt signaling pathway
that was suggested to act in concert with protein kinase C
(PKC)-α [49]. PKC-α isoform has a role in mediating EPO-
induced erythroid diﬀerentiation of the CD34+ progenitor
cells from human bone marrow [50]. Furthermore, during
Epo-dependent phase of erythroid diﬀerentiation, Epo and
SCF suppressed activity of p38α whereas during the Epo-
independent terminal-phase of diﬀerentiation, p38α and
-δ phosphorylation was increased. This demonstrated both
isoformsofp38functiontopromotethelate-stagediﬀerenti-
ation of primary erythroid progenitors [51]. This conﬁrmed
previous report, showing that activation of p38 as well as
JNKs was required for Epo-induced erythroid diﬀerentiation
in SKT6 cells [52].
Also involved in erythropoiesis regulation is the
Jak/STAT5 signaling pathway which is rapidly activated after
Epo binding to EpoR, on erythroid progenitors. In mice
models, it was shown that early erythroblasts survival as
well as normal erythropoiesis was controlled by STAT5 [53].
Indeed, silenced STAT5 expression in mice led to an increase
in early erythroblast numbers which nevertheless failed to
progress in diﬀerentiation giving rise to anemia. Silenced
STAT5-mediated anemia was correlated to down-regulation
of the antiapoptotic bcl-XL gene and to increased apoptosis.
This supported the Jak/STAT5 pathway implication in the
regulation of diﬀerentiation by preventing pro-erythroblasts
apoptosis. On the other hand, bcl-XL-mediated inhibition
of apoptosis in erythroid cells was shown to be a response
to Epo/EpoR-induced inhibition of the caspase cascade
ampliﬁcation [54]. Indeed, caspase-3 activation led to
degradation of the transcription factors SCL/TAL-1 as well
as GATA-1, which regulate bcl-XL gene expression [54, 55].
In fact, Tal-1 protein was shown phosphorylated in response
to Epo stimulation [56] by PI3K-activated MAPK signaling
pathway [57].Mediators of Inﬂammation 3
Stimulation of signaling pathways by Epo/EpoR, SCF/Kit
or other stress conditions results in the activation/repression
o fm a n yt r a n s c r i p t i o nf a c t o r ss p e c i ﬁ c a l l yi n v o l v e di ne r y -
thropoiesis regulation. The zinc ﬁnger protein GATA-1
is considered as one of the most critical transcription
factors in erythropoiesis as well as megakaryopoiesis. Besides
GATA-1 that belongs to the GATA-family of transcription
factors, GATA-2 is also involved in erythropoiesis and
megakaryopoiesis regulation [58, 59]. Both GATA-1 and
GATA-2 transactivation activities require interaction with
friend of GATA (FOG)-1 cofactor [60, 61]. In addition,
both transcription factors have GATA binding sites in their
cis-acting elements allowing a cross-regulatory mechanism
in which GATA-1 can control the expression of GATA-2
and vice versa. GATA-2 is overexpressed in early immature
hematopoietic progenitors to ensure their maintenance and
proliferation whereas GATA-1 is essential for the survival of
erythroid progenitors as well as the terminal diﬀerentiation
of erythroid cells [59, 62]. In fact, increased expression of
GATA-2 determines megakaryocytic diﬀerentiation whereas
its down-regulation is required for erythroid diﬀerentiation
[58]. Recently, a role for GATA-2 in the regulation of quies-
cence in human hematopoietic stem and progenitor cells has
been reported [63]. GATA-1 activation has been correlated
to its phophorylation. Epo-induced phosphorylation of
GATA-1 is important for maturation of fetal liver erythroid
progenitor cells, speciﬁcally on serine 310 by PI3K/AKT that
enhances GATA-1 transcriptional activity in vitro and in ery-
throid cells [64]. However, GATA-1 acetylation by CBP/p300
is also described as crucial for the binding to its DNA
target GATA sequence possibly involving phosphorylation
[65–67]. Moreover, phosphorylation of GATA-1 could be
mediated by MAPK pathway, as an ubiquitination signal for
its proteasomal degradation [68]. On the other hand, besides
FOG1, GATA-1 activity is highly dependent on interaction
with many cofactors including EKLF, SP1, CBP/p300, Lmo2,
Ldb1, RUNX1, Fli1 and PU.1, which represent a part of
the best-described interacting proteins. These cofactors can
constitute a very complex network regulating erythropoiesis
and megakaryopoiesis, by promoting or repressing GATA-1
activity [69–73]. Particularly, PU.1 is a strong inhibitor of
GATA-1 DNA-binding activity and erythroid diﬀerentiation
[74, 75].
3. TNFα DirectlyInhibitsErythropoiesis
Evidences for TNFα inhibiting eﬀect on erythroid diﬀeren-
tiation have been described 30 years ago. In 1987 Blick et
al. observed a decrease in hemoblobin synthesis in cancer
patients treated with TNFα (phase 1) [13] while in vitro
study showed that TNFα inhibited the formation of BFU-
E cells [28]. Later, Xiao et al. reported that TNFα inhibited
the glycophorin A+ cells in correlation with an inhibition
of erythropoiesis [76]. Moreover, an increasing hemoglobin
level has been observed in patients suﬀering from anemia of
chronic disease after an anti-TNF treatment [77]. The reduc-
tion of Epo production in the kidney partially explained
the eﬀect of the pro-inﬂammatory cytokins including TNFα
[20]. La Ferla et al. reported that TNFα-mediated inhibition
of Epo production in HepG2 cells was a consequence of
GATA-2 and NF-κB over-expression [78]. This was to some
extent completed by Imagawa et al. who showed that TNFα-
mediated inhibition of Epo gene expression could be rescued
by the K-7174, a “GATA-speciﬁc inhibitor,” in HepG3 cells
[79]. However, TNFα inhibiting eﬀe c to ne r y t h r o i dd i ﬀer-
entiation also occurs by a direct action on cells, including
hematopoietic progenitors and cell lineages. Recently, Tsopra
et al. published a study on disease-related anemia in chronic
lymphocytic leukemia (CLL) patients. They showed that
CLL-related anemia might result from the direct suppressive
eﬀect of TNFα on the erythroid development in early stages
of erythropoiesis instead of an intrinsic defect of erythroid
precursors to diﬀerentiate or to respond to Epo stimulation
[80]. In fact, the results from Rusten and Jacobsen in 1995
suggested for the ﬁrst time that TNF-α-induced inhibition
of erythroid colony formation could be directly mediated on
the progenitor cells [26]. By using BFU-E colony stimulated
by various cytokine combinations (SCF, IL-3, IL-9) with
Epo, they showed that TNFα inhibiting eﬀect was mediated
predominantly through p55-TNF receptor (TNFR1). This
result was correlated to the implication of NF-κBt r a n -
scription factor, a TNFα/TNFR1 activated product, in the
inhibition oferythroidspeciﬁcgenes.Especially,transfection
assays in K562 cells showed the suppression of human α-
like globin promoters by the NF-κBp a t h w a y[ 81]. On the
other hand, our group recently showed that TNFα inhibited
hemoglobin production in aclacinomycin-induced K562
cells[25].Aclacinomycinisananthracyclinthatwasreported
to induce over-expression of the key transcription factors for
erythropoiesis, GATA-1 and NF-E2 in this cell line [82, 83].
Interestingly, the cytokine inhibiting eﬀect was correlated to
the down-regulation of GATA-1 and NF-E2. These results
were conﬁrmed in the erythroleukemia cell lines HEL and
TF-1 [23, 24]. Furthermore, studies in K562 and HEL cells
stronglysuggestedGATA-1asakeytargetofTNFαinhibiting
eﬀect achievement (Figure 1). Indeed, the cytokine induced
a decrease in the expression of FOG-1, an essential cofactor
of GATA-1, a down-regulation of GATA-1 by proteasomal
degradation and a reduced acetylation level of GATA-1 while
the transcription factor GATA-2 was over-expressed [24]. In
addition, an inhibition of EpoR, α-a n dγ-globin, erythroid-
associated factor (ERAF), hydroxymethylbilane synthetase
(HMBS), and glycophorin A (GPA) erythro-speciﬁc genes,
was found in the Epo-dependent TF-1 cell line [23]. These
results were concomitant with a reduction of GATA-1/FOG-
1 complex formation and a signiﬁcant and rapid increase in
p38MAPKphosphorylation.Theinhibitionofp38abrogated
the inhibitory eﬀect of TNFα on GATA-1 as well as γ-globin
expression in Epo-induced TF-1 cells.
Thus, data related to TNFα-mediated inhibition of ery-
thropoiesis show the indirect but also the direct involvement
ofthiscytokineinanemiadevelopment.Howeverdespitefew
publications describe the molecular mechanisms implicated,
they clearly show the role of TNFR1 and NF-κB, as well
as other speciﬁc transcription factors, namely GATA-1 and
FOG1,NF-E2,andGATA-2.Notably,thedown-regulationof
GATA-1atdiﬀerentlevelsbyTNFαmightaﬀecterythroblasts
programmed cell death besides diﬀerentiation, by triggering4 Mediators of Inﬂammation
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Figure 1: TNFα inhibits erythropoiesis by direct and indirect eﬀects. In the indirect eﬀect, TNFα activates the transcription factors NF-κB
and GATA-2, which were also reported as involved in Epo production inhibition by blocking HIF1α in vitro. Low level of Epo decreases the
EpoR-mediated signaling pathways resulting among others, in the down-regulation of GATA-1, and consequently in a possible deregulation
of EpoR expression. The direct eﬀect of TNFα via its receptors TNFR1/2 has also been demonstrated. The activation of the NF-κB canonical
pathway (p50/p65) inhibits erythro-speciﬁc genes expression as globin genes. TNFα was also reported as activating GATA-2 whose over-
expression is known to prohibit erythropoiesis in favor of megakaryopoiesis. Conversely, TNFα inhibits GATA-1 in K562, HEL and TF1 cells.
GATA-1 expression is aﬀected as well as its acetylation (Ac), and its interaction with FOG1 that was suggested to be degraded by proteasome.
Moreover, TNFα was shown to rapidly stimulate p38MAPK phosphorylation in correlation with γ-globin gene down-expression while Epo
had a delayed eﬀect on this kinase activation. The combined eﬀects of TNFα result in the decrease in erythro-speciﬁc genes expression and
hemoglobin production.
early apoptosis via down-expression of the anti-apoptic bcl-
XL gene whose transcription is regulated by GATA-1. Obvi-
ously, TNFα causes anemia independently of inhibition of
Epo production. Further studies on molecular mechanisms
using hematopoietic stem/progenitor cells should allow
bettering understanding of how TNFα-mediated inhibition
of erythropoiesis occurs.
4. TRAIL-MediatedAnemia InvolvesApoptosis
TNF-relatedapoptosis-inducingligand(TRAIL),alsoknown
as Apo2L, is a member of the TNF-related proteins initially
identiﬁed and characterized by Wiley et al. in 1995. It is
a type II membrane protein that is also expressed as a
soluble protein. Both forms are able to induce apoptosis
in a wide variety of transformed cell lines of diverse
origins [84] including several hematopoietic lineages [85].
TRAIL exhibits structural and functional similarities with
Fas ligand (FasL/CD95L), including the use of FADD as
adaptor molecule [86–90]. It interacts with four high-
aﬃnity membrane receptors (R) TRAIL-R1 (DR4), TRAIL-
R2 (DR5), TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) that
belong to the apoptosis inducing TNF-receptor family. A
study on TRAIL implication in the homeostatic control
of hematopoiesis showed its negative eﬀect on normal
erythropoiesis, in a diﬀerentiation-stage speciﬁc manner
[18].
Moreover, studies on TRAIL activity and expression
in myelodysplastic syndromes (MDS) patients have been
reported. MDS are characterized by impaired erythropoiesis
leading to anemia, the major clinical feature in this syn-
drome. By analyzing MDS marrow, Zang et al. showed that
TRAIL induced extensive apoptosis, including in the blast
cell population while no increase in apoptosis was observed
in normal marrow [91]. They correlated this observation
with high levels of surface expression of agonistic receptors
TRAIL-R1 and -R2 in MDS marrow, which could explain
the selective killing of tumor cells by TRAIL. On the
other hand, the authors suggested that apoptotic response
could be modiﬁed by the variations in the anti-apoptotic
protein FLIP expression in addition to the cell-surface-
receptor expression in MDS. Indeed, they found that FLIP
was expressed in marrow from healthy donors whereas the
protein was not detectable in most of the MDS marrows.
Together, the results suggested that TRAIL might play a role
in the regulation of hematopoiesis in MDS marrow. In the
same way, another study showed that TRAIL expression was
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patients and released at the bone marrow level probably
contributing to the degree of anemia. In fact, MDS bone
marrow-conditionned media with released soluble TRAIL,
added to a normal CD34-derived erythroblasts culture, led
to impairment of erythroid maturation, as assessed by the
levels of GPA. This demonstrated the role of soluble TRAIL
in aﬀecting the maturation of erythroid precursors in MDS
patients [92].
Acomparativestudyinmultiplemyeloma(MM)patients
with or without anemia, showed an inverse correlation
between the expression of TRAIL (and Fas-L) in malignant
plasma cells and the relative erythroblast numbers, with a
higher percentage of immature erythroblasts in enriched
erythroblast populations from anemic MM patients [93].
A downexpression of GATA-1 transcription factor has been
detected in immature erythroblasts from MM patients with
severe anemia. They ascribed this decrease to Fas-L and/or
TRAIL-mediated cleavage of GATA-1 native form. Indeed,
GATA-1 can be cleaved by several caspases in CD34+ cell-
derived erythroblasts, following their treatment with TRAIL
leading to maturative arrest [55].
Secchierro et al. found that TRAIL-R3 and -R4 were
never expressed neither on the surface of freshly puriﬁed
CD34+ hematopoietic progenitor cells nor on GPA+ ery-
throblasts at early-intermediate and late culture times [94].
On the contrary, they suggested that TRAIL-R2 probably
played a role in erythroid development since this receptor
was found expressed at early phases of erythroid diﬀer-
entiation with a progressive increase along the erythroid
maturation. Conversely, TRAIL-R1 was detectable only at
early phases of erythroid development. The authors reported
that TRAIL induced MAP kinase ERK1/2 activation in
primary normal erythroblasts, but not p38 or JNK. Con-
sidering that ERK1/2 pathway was shown as involved in
the early proliferative phases of erythropoiesis [95]a n d
in the inhibition of terminal erythroid diﬀerentiation [52,
96–98], they suggested that TRAIL-mediated activation of
ERK1/2 was responsible for the inhibiting eﬀect of TRAIL
on normal erythroid development. On the other hand, the
activation of ERK1/2 by TRAIL at all the stages of erythroid
development correlated with the expression of TRAIL-R2.
TogetherthesestudiesclearlyindicatethatTRAILplaysarole
in erythropoiesis inhibition and anemia development via its
receptor R2 and probably R1.
5. Indirect Action of Interferon-Gamma
Interferon (IFN)-γ has been reported as inhibiting growth
and diﬀerentiation of erythroid precursor cells [99, 100]
as well as a potential mediator of hematopoietic failure
in aplastic anemia (AA). AA belongs to the bone marrow
failuresyndromes,characterizedbyabreakdowninthestem-
and progenitor-cell compartments. In fact, several authors
had suspected the role of IFN-γ in erythropoiesis inhibition
according to an elevated production of the cytokine by lym-
phocytes in AA patients while it was absent in normal bone
marrow[100–105].AmicroarrayanalysisofRNA-expression
proﬁle in CD34+ and bone marrow stroma cells showed
that IFN-γ induced an increase in the expression of Fas and
TRAIL genes, known to be involved in anemia promotion
[106]. Furthermore, Felli et al. reported that the TNF family
members TRAIL and TWEAK (Apo-3 ligand) as well as its
receptorFn-14wereinvolvedinIFN-γ-mediatedsuppression
of erythropoiesis in puriﬁed human erythroblasts [107].
This was in correlation with the inhibition of growth and
diﬀerentiation of the erythroblasts. Moreover, they could
restore erythroid cell survival, proliferation and maturation,
inhibited by IFN-γ, performing combined neutralization of
TWEAK, TRAIL and FasL/CD95L. This pointed out the role
of the three proteins as eﬀectors of IFN-γ in erythropoiesis
suppression. On the other hand, the modulation of adhesion
molecule genes expression (ICAM1 and VCAM1, integrin-
α5 and integrin-β3) in stromal cells treated with IFN-γ [106]
correlated with previous works demonstrating the altering
eﬀect of IFN-γ (and TNF-α) on the adhesive mechanism
[108]. Therefore it was assumed that the cytokine may
aﬀect the function of bone hematopoietic stem cells by
disturbing their adhesion to the marrow microenvironment
in AA patients [106]. Until now, in opposition to TNFα
and TRAIL, the direct eﬀect of IFN-γ on erythroblastic
cells at the molecular level has not been demonstrated.
However, IFN-γ and also IL-6 are known to activate the
phosphorylation of the transcription factor STAT3. It was
recently reported that STAT3 activation silenced γ-globin
gene expression in primary erythroid cells [109]a n df o e t a l
hemoglobin production in K562 cells. In these experiments
the eﬀect of STAT3 was reversed by GATA-1 induced over-
expression [110].
6. Inﬂammation, OxidativeStress andAnemia
One of the major proteins of red blood cells is the acidic
peroxidoxin, which plays a role in the response against
oxidative stress. The expression of this protein is induced
early in erythropoiesis, prior to hemoglobin production
suggesting the importance of the protection of erythroid
progenitors against oxidative stress [111]. Erythropoiesis
regulation is indeed very sensitive to oxidative stress and
the release of proinﬂammatory cytokines in neoplastic
patients as well as chronic inﬂammatory diseases are often
associated with increased production of reactive oxygen
species (ROS) (H2O2 and HO
•)[ 112, 113]. Moreover, TNFα
links inﬂammation to carcinogenesis through ROS [114]
and it was reported that TNFα elevates ROS production
in glioma cells [115]. However, it appears that the role
of oxidative stress is complex since reactive oxygen species
may either trigger [116]o rp r e v e n t[ 117, 118]h e m a t o p o i -
etic diﬀerentiation and proliferation. It was demonstrated
that the increase in oxidative stress and free radicals are
associated with disorders implicated in anemia of chronic
disease [119] while anthracycline- and butyrate-mediated
diﬀerentiation of K562 cells was prevented by anti-oxidant
compounds [120]. This last study suggested that butyrate- or
anthracycline-generated oxidative stress was involved as the
ﬁrst step in the irreversible erythroid diﬀerentiation process.
Ontheotherhand,Dallalioetal.reportedthatinﬂammatory
cytokine-mediated anemia of chronic disease may occur
through modulation of oxidative stress [121]. Elorza et al.6 Mediators of Inﬂammation
also demonstrated the importance of the ROS modulation
during erythropoiesis, by studying the uncoupling protein
(UCP)2 role [122]. Its expression leads to a decrease in
mitochondrial superoxide and it was previously shown that
UCP2 was related to erythroid diﬀerentiation since it was
induced by GATA-1 activation in the proerythroblast G1E-
ER cell line [123]. UCP2 deﬁciency in progenitor cells at
the Epo-dependent phase of erythropoiesis led to a decrease
in cell proliferation in correlation with ERK reduced phos-
phorylation, which is known as a ROS-dependent cytosolic
regulator of cell proliferation. A relationship between UCP2
and the MAPK/ERK pathway has been reported in the case
of elevated inﬂammatory response and inhibition of UCP2
could lead to the development of anemia [124].
7. Conclusions
Obviously pro-inﬂammatory cytokines have a negative
eﬀect on erythropoiesis development leading to anemia
in multiple diseases including chronic infections, chronic
inﬂammatory diseases, myelodysplastic syndromes, and
malignancy. The pathophysiological eﬀects of cytokine over-
expressions have been well described but the mechanisms
surrounding cytokine-mediated induction of anemia remain
largely unknown. Many studies show that erythroid colony
formation in response to Epo is impaired in the presence
of pro-inﬂammatory cytokines [125–127] without provid-
ing molecular mechanisms. In this paper we review data
available on the molecular mechanisms involved in the
defect of erythropoiesis due to three pro-inﬂammatory
cytokines TNFα, TRAIL, and IFNγ. Nonetheless, other pro-
inﬂammatory cytokines have been involved in erythropoiesis
defect, such as the interleukin (IL)-6 [112]. Impaired ery-
thropoiesis is most likely due to apoptosis induction, cell
growth inhibition and EpoR downregulation as a result of
a local increased production of the cytokines, but also iron
metabolismdamage.Inallcasespro-inﬂammatorycytokines
aﬀect Epo either by inducing inhibition of its production
by kidney or by preventing its physiological functions at the
cellular level. Indeed, cytokines activate signaling pathways
thatcanhavecommonfeaturewithEpoR-triggeredsignaling
pathways leading to cell proliferation, diﬀerentiation, or
survival.
Regulation of erythropoiesis occurs in a tightly time
dependent manner and changes in the timing of one
speciﬁc signaling intermediate activation can disturb cell
diﬀerentiation process. Thus, it is known that both TNFα
and Epo activate p38MAPK phosphorylation. We could
recently observe that this kinase was very early activated by
TNFα (10 minutes) while Epo-mediated activation occurred
muchlaterinTF-1cells(48hours).Thisresultwascorrelated
to the inhibiting eﬀect of TNFα on Epo-induced erythroid
diﬀerentiation in TF-1 cells [23]. Thus, how speciﬁc signal
transduction pathways of pro-inﬂammatory cytokines can
interact with EpoR ones to prevent erythroid diﬀerentiation
is an interesting issue. On the other hand, pro-inﬂammatory
cytokines activate diverse transcription factors that can have
contradictory eﬀects in regard to the cell intention. For
example, NF-κB, which is typically activated by cytokines,
was reported involved in the inhibition of Epo production
[78] and the repression of globin genes expression [81].
Moreover, GATA-1/GATA-2 balance, which is a key element
for erythropoiesis regulation was shown aﬀected by TNFα
[24].
On the other hand, besides erythroid genes expression,
GATA-1 and TAL-1/SCL are implicated in apoptosis regula-
tion by controlling bcl-XL gene expression. Common pro-
apoptotic properties of pro-anemia cytokines seem involved
in erythropoiesis delay or prevention. Therefore, cytokine-
mediated activation of caspases and Epo-induced GATA-
1 expression might represent a crossing point in which
GATA-1 cleavage would lead to down-regulation of Bcl-Xl
expression and then apoptosis activation. Studying the pro-
inﬂammatory cytokines eﬀect at the transcriptional level
should allow understanding how the erythroid speciﬁc genes
are repressed and how the pro-apoptotic genes are acti-
vated. In addition to transcription factors network analysis,
especially GATA-1, micro-RNAs implication could be taken
in consideration according to the expected role of these
molecules in erythropoiesis [128–135].
Inconclusion,themodulationofEpo-mediatedsignaling
pathways as well as transcription factors and cofactors by
pro-inﬂammatory cytokines are required to achieve inhibi-
tion of erythroid diﬀerentiation. Several in vitro and in vivo
studies demonstrated that high levels of proinﬂammatory
cytokines and increased oxidative stress contribute both to
the development of anemia and to the resistance to recom-
binant human hrEpo. The complexity of this phenomenon
provides multiple targets for potential drugs in order to
inhibit cytokines eﬀect and/or to promote erythroid diﬀer-
entiation, mainly in cancer-related anemia. Indeed, despite
hrEpoisclinicallyeﬃcientforanemiatreatmentitisstrongly
suspected to induce tumor cell proliferation. Therefore
studies of the mechanisms involved in the inhibiting eﬀect
of cytokines on erythropoiesis are essential to intend future
anti-anemic treatment, at least for cancer patients.
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